|
Nov 13
|
4 Large Drug Stocks Likely to Sail Through Industry Woes
|
|
Nov 13
|
US STOCKS-Futures dip as focus shifts to inflation data
|
|
Nov 13
|
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
|
|
Nov 13
|
Scientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports
|
|
Nov 13
|
Better Buy Now: Novo Nordisk vs. Eli Lilly
|
|
Nov 11
|
Cautious Investor? 2 Safe Stocks You Also Can Count on For Growth
|
|
Nov 10
|
Top Funds Can't Get Enough Of Amazon — And This Intelligence Play
|
|
Nov 10
|
Where Will Eli Lilly Be in 5 Years?
|
|
Nov 10
|
Optum Rx moves 8 insulins to preferred formulary status as pressure mounts on PBMs
|
|
Nov 10
|
UPDATE 1-EU regulator recommends Eli Lilly's Mounjaro for weight management
|
|
Nov 10
|
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
|
|
Nov 10
|
The Stock-Split Stock Behind Ozempic and Wegovy Could Be Yours for Just $100
|
|
Nov 10
|
Look Out, Ozempic and Wegovy: Eli Lilly Has a New Weight-Loss Drug in Town
|
|
Nov 10
|
British regulator confirms review of new pen for Lilly's Mounjaro drug
|
|
Nov 10
|
Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.
|
|
Nov 10
|
UPDATE 4-Novo Nordisk invests $6 bln in Wegovy production, still far below demand -CEO
|
|
Nov 9
|
Approval for Eli Lilly obesity drug sets up rival to Wegovy
|
|
Nov 8
|
Earnings Estimates Come Under Pressure
|
|
Nov 8
|
FDA approves Eli Lilly's Mounjaro for weight loss
|
|
Nov 8
|
Eli Lilly Shares Hit All-Time High After FDA Approves Drug for Weight-Loss Treatment
|